In Washington state, the pursuit to legalize psychedelic mushrooms has encountered significant obstacles amid a complex landscape of differing visions, cost concerns, and apprehensions regarding pharmaceutical interests taking control of naturally occurring psychedelics.
Although statewide legislative efforts have yet to gain momentum, a burgeoning underground network of advocates and activists is actively working toward decriminalization at the local level.
In recent years, clinical trials have increasingly demonstrated that psilocybin, the key psychedelic compound found in mushrooms, holds promise for treating severe mental health conditions including depression, anxiety, post-traumatic stress disorder (PTSD), and addiction.
Adding to the momentum, Dr. Sunil Aggarwal, a palliative care physician associated with Seattle’s AIMS Institute, has initiated a petition aimed at reclassifying psilocybin from a Schedule I to a Schedule II drug.
This classification change could facilitate enhanced research opportunities and broaden access to psilocybin therapies.
Dr. Aggarwal may find support in Health and Human Services Secretary Robert F. Kennedy Jr., who has publicly advocated for the legalization of psychedelics for mental health treatment.
These circumstances have led many to ponder whether Washington state is on the verge of a psychedelic renaissance.
Dr. Charissa Fotinos, a family practice physician who specializes in addiction medicine and was also the chair of the Washington Psilocybin Task Force in 2023, expressed surprise at the extensive reach of the psychedelic movement.
“I had no idea the tendrils this thing has,” Fotinos remarked, noting the significant underground network that exists even as the movement strives for broader public recognition.
The Washington Psilocybin Task Force, composed of professionals from diverse fields including medicine, social work, and state governance, was established to review the latest clinical evidence on psilocybin and assess potential regulatory frameworks for its clinical use.
Despite the task force’s focus on the potential therapeutic applications of psilocybin, Fotinos acknowledged that the discussion quickly expanded beyond clinical effectiveness to encompass a profound social movement.
As interest in these substances grows, psychedelic societies have emerged across the nation.
The Global Psychedelic Society lists approximately 300 groups worldwide, with 172 located in the U.S. and 10 within Washington state.
Fueled by the belief in the healing powers of “entheogens,” substances that induce altered states of consciousness, these societies advocate for personal connection, community sharing, and re-establishment of spiritual and natural connections.
Entheogens encompass more than just psychedelic mushrooms, including substances like ayahuasca, ibogaine, and mescaline-containing cacti.
Erin Reading, a co-founder of the Port Townsend Psychedelic Society, was inspired by the early decriminalization efforts in Oakland, California, which fueled her pursuit of policy changes in Washington.
Reading also serves on the board of a nonprofit called REACH Washington, which opposed state legislative measures that did not incorporate decriminalization into their proposals.
Her organization sought to promote a statewide initiative aimed at decriminalizing entheogens, but that endeavor faced financial challenges and stalled.
“I am all about community access, and people having access to these plants without having to pay a lot of money or be restricted to specific contexts,” Reading stated.
The Port Townsend Psychedelic Society engages the community through educational classes, safe-use gatherings, and advocacy for equitable access and decriminalization.
Reading emphasized the importance of education in minimizing the risks associated with psychedelics and fostering a supportive community environment.
In December 2021, due in large part to the efforts of this psychedelic society, Port Townsend adopted a resolution to decriminalize entheogens, with Jefferson County following suit shortly thereafter.
Reading highlighted the positive potential of local psychedelic communities, where individuals can forge real relationships and access necessary resources should they choose to explore psychedelic experiences.
Kody Zalewski, a Seattle-based policy expert and member of the Washington psilocybin task force, is a key advocate for grassroots legal reform across the state.
Zalewski believes that effective change surrounding psychedelic policies must originate from local communities, gradually ascending to higher governmental levels.
“Reaching a tipping point at local governance will create enough momentum to catalyze change at state levels,” he explained.
As the co-director of the Psychedelic Medicine Alliance of Washington, Zalewski also contributed to the successful passage of a resolution in Seattle to deprioritize arrests connected to psychedelic substances.
Their efforts are now focused on generating similar measures in King County.
Tatiana Luz, co-director of the alliance, also manages a Seattle group known as The Zome that facilitates community discussions about psychedelics in natural settings.
Luz sees a cultural shift toward a broader acceptance of psychedelics as a critical prerequisite for any advancements in policy.
“Psychedelic experiences have offered me healing as well as a vehicle for exploring the complexity of consciousness and existence,” she shared.
Meanwhile, April Pride is working to mainstream the conversation around psychedelics through educational initiatives.
Pride hosted several “Psychedelic Salons” in Seattle, engaging artists, doctors, and researchers in discussions around the benefits of psychedelics in both creativity and mental health therapies.
Having founded SetSet, a clinician-backed psychedelic education and integration community aimed at benefiting women’s health, Pride also hosts a podcast covering various aspects of psychedelics including safe preparation and dosages.
With an emphasis on microdosing, Pride emphasizes the empowerment of mental health through safe engagement with psychedelics in community settings.
Reports from sources like RAND indicate that around 8 million people used psilocybin in the previous year, with a significant subset experimenting with microdosing.
Research is beginning to suggest that microdosing may enhance neuroplasticity, leading to alternative responses to everyday stresses.
On the flipside, macro-dosing, administered with professional guidance, has shown promising results in alleviating symptoms for those grappling with severe mental health issues.
Dr. Nathan Sackett, a notable figure at the University of Washington’s psychiatry department, has led trials demonstrating the efficacy of psychedelic-assisted therapy, particularly for addiction and mood disorders.
In one specific clinical trial, he noted a striking reduction in depressive symptoms among healthcare workers exposed to the stress of the pandemic through controlled psychedelic experiences.
Participants in these trials reported significant life changes as a result of the transformative potential of the psychedelic experience, allowing them a moment of clarity that had previously been obscured by daily pressures.
The center’s upcoming psilocybin trial aims to examine its effects on individuals coping with both PTSD and alcohol use disorders, emphasizing the importance of this research for vulnerable populations.
Despite the benefits being revealed, psilocybin’s current classification as a Schedule I drug under the Controlled Substances Act complicates research efforts and access.
Dr. Aggarwal has navigated numerous bureaucratic challenges in his attempt to reclassify psilocybin and recently received a renewed review opportunity from the DEA.
After a court requested that the agency reconsider their initial refusal, the review has moved to the Department of Health and Human Services and the FDA, both of which may play a pivotal role in shaping future psilocybin access.
“If we can achieve reclassification, it’s a potential game-changer for my patients,” Aggarwal expressed, underscoring the life-altering capacity of psilocybin for those facing terminal illnesses.
He believes that psilocybin can substantially alleviate anxiety and existential pain, offering a renewed perspective to patients facing death.
In contrast, Oregon has emerged as both a leader in psilocybin legalization and a cautionary tale regarding potential pitfalls tied to commercialization.
As the first state to decriminalize and legalize supervised psilocybin use, Oregon’s experience has sparked concern over access equity and affordability.
Legal psilocybin experiences in Oregon can cost upwards of $2,500, which can place these valuable therapeutic experiences beyond the reach of many.
This commercialization, according to critics, risks transforming psychedelics into commodities stripped of their traditional communal and spiritual roots.
Senator Jesse Salomon has voiced concerns that the trajectory of psilocybin legalization may mirror the commercialization observed in Washington’s cannabis industry.
His sentiment reflects a desire for thoughtful policy design that prioritizes public health and accessibility rather than profit-driven motives.
As discussions continue in Olympia, advocates for psilocybin decriminalization are celebrating achievements at the local level.
Cities like Seattle, Port Townsend, and Jefferson County have already made significant strides in reducing enforcement around psilocybin, with efforts to replicate this success in places like King County and Spokane underway.
Reflecting on the momentum, Reading remarked on the palpable energy within the community: “We’re not on the cusp anymore; we’re in it now.”
With grassroots support growing and narratives shifting, the movement reinforces the idea that psychedelics can serve as powerful tools for healing and connection in society.
image source from：https://www.kuow.org/stories/washington-cities-are-decriminalizing-magic-mushrooms-could-a-psychedelic-renaissance-take-hold-statewide
